Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control
Information source: Tehran University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Paroxysmal Supraventricular Tachycardia
Intervention: Verapamil (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Tehran University of Medical Sciences
Summary
PSVT is a common rhythm disorder in emergency department which can be recurrent in some
cases.
Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very
short acting agent.
Providing a complementary medication to decrease the rate of recurrence of PSVT after its
initial control will be promising.
This study evaluates the role of the oral Verapamil in recurrence control of PSVT in
emergency situations.
Clinical Details
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Recurrence Control
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age>18 years old
- PSVT on emergency department presentation
Exclusion Criteria:
- Instability in hemodynamic status
- Allergy to Verapamil
Locations and Contacts
Additional Information
Starting date: October 2010
Last updated: November 12, 2012
|